Monograph
R03AK04 - Salbutamol and Sodium Cromoglicate |
Propably not porphyrinogenic |
PNP |
Rationale
salbutamol: Rather low dose, in large parts excreted unmetabolized. No data pointing to clinical CYP-interaction. Four references consider it safe. ipratropium: Hydrophilic substance, insignificant systemic exposure.
Chemical description
salbutamol: Adrenergic beta-receptor stimulating agent used in asthma. Administered as salbutamol sulfate in micronized form in inhalation aerosol (2,5 - 5 mg/dose). No clinical data pointing to CYP-interaction. About 35% of the dose is excreted in unchanged form in urine. ipratropiumbromide Ipratropiumbromide, a quarternary ammonium compound with anticholinergic properties. used in inhalation aerosol (21-42 ug/dose) as bronchodilator in chronic obstructive pulmonary disease and in asthma. No data poiinting to CYP-interaction. salbutamol: EPI-list: safe South African list: use French list: authorized. Kauppinen and Mustajoki. Prognosis of acute porphyria... Medicine 1992; 71: 1-13: tolerated (n=2)
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
© NAPOS 2025